Traditionally, patients with rheumatoid arthritis (RA) have been treated with immunosuppressive drugs, such as corticosteroids, disease-modifying antirheumatic drugs (DMARDs; eg, methotrexate), and nonsteroidal anti-inflammatory drugs, but in the last 1 to 2 decades, biologic DMARDs-consisting of several cytokine inhibitors and other immune modulators-have been added to this list.
  • Secukinumab Effective in Ankylosing Spondylitis
  • Vitamin D Supplementation in Juvenile-Onset SLE
  • Health-Related Quality of Life in Childhood-Onset Lupus
  • Provider's Communication Style and Patient Self-Efficacy
  • Postoperative Care Navigation for Total Knee Arthroplasty
Gout is a common and painful condition that is manageable, and treatment guidelines are available. Despite this, several studies suggest management is suboptimal.
Patients with psoriatic arthritis (PsA) who achieved persistent minimal disease activity (MDA) on golimumab treatment in the GO-REVEAL trial had better long-term benefits, including functional improvement, global assessment, and radiographic outcomes, than those who did not, according to a post hoc analysis of the GO-REVEAL trial.
The immune system of pregnant women becomes altered to tolerate fetal antigens while still being able to fight infections, and these immunomodulatory consequences influence autoimmune rheumatic diseases.
Patients with rheumatoid arthritis (RA) or osteoarthritis (OA) routinely need joint pain relief, and joint replacement surgery is often required for those with severe disease; however, there are no effective strategies for preventing disease progression.
The rates of total knee replacement (TKR) continue to rise in patients with rheumatoid arthritis (RA) and osteoarthritis (OA). Studies done in previous years suggested that TKR was less successful in improving function in patients with RA than in those with OA. The good news is that a new study finds similar and excellent outcomes for TKR in RA compared with OA in the contemporary era.
On February 9, 2016, Celltrion's infliximab biosimilar CT-P13 was recommended for approval by a vote of 21 to 3 by the US Food and Drug Administration's (FDA) Arthritis Advisory Committee.
The age-related cartilage wear that occurs in macroscopically normal joints and is evident at the superficial zone indicates that the wear-protective function of synovial fluid (SF) and wear resistance of cartilage changes with aging, and may lead to osteoarthritis (OA).
A recent systematic review suggests that taking action in a variety of nonpharmacologic ways can reduce fatigue associated with systemic lupus erythematosus (SLE).
Page 1 of 2
Results 1 - 10 of 16
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology